SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secret...
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. Abstract OverviewAbstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical sustained release Gemci...
Globaler Innovationsschub im Energiebereich: TERA-Award mit rekordverdächtigen 785 Einsendungen HONGKONG, April 27, 2025 (GLOBE NEWSWIRE) -- Der diesjährige TERA-Award hat Innovatoren aus aller Welt angezogen und damit frühere Teilnahmerekorde gebrochen – ein Beleg für den zunehmenden globalen Bedarf an klimatechnischen Lösungen. Der Wettbewerb für intelligente Energielösungen beendete Anfang April die Bewerbungsphase mit 785 Einreichungen aus 76 Ländern und Regionen und verzeichnete damit die höchste Beteiligung in seiner vierjährigen Geschichte. Diese Zahlen stehen stellvertretend für ...
Auge mundial de la innovación energética: el premio TERA-Award bate un récord con 785 candidaturas HONG KONG, April 27, 2025 (GLOBE NEWSWIRE) -- Como prueba de los crecientes esfuerzos internacionales por encontrar soluciones tecnológicas al problema del clima, la edición de este año del premio TERA-Award ha atraído a innovadores de todo el mundo, superando con creces los récords de participación anteriores. El concurso de energía inteligente cerró el plazo de inscripción a principios de abril con 785 candidaturas procedentes de 76 países y regiones, la cifra más alta en sus cuatro años d...
Un record de 785 candidatures au TERA-Award illustre l'engouement international pour l'innovation énergétique HONG KONG, 27 avr. 2025 (GLOBE NEWSWIRE) -- Cette année, TERA-Award a attiré des innovateurs du monde entier et a fait exploser les records de participation des éditions précédentes, illustrant un élan mondial accru en faveur de solutions technologiques climatiques. L'appel à candidatures de ce concours autour de l'intelligence énergétique a été cloturé début avril. 785 demandes ont été soumises, provenant de 76 régions et pays différents, soit le record ultime de ses quatre année...
Impennata globale nell'innovazione energetica: il TERA-Award attira 785 candidature da record HONG KONG, April 27, 2025 (GLOBE NEWSWIRE) -- A testimonianza dell'accelerazione della spinta globale verso le soluzioni tecnologiche per il clima, il TERA-Award di quest'anno ha attirato innovatori da tutto il mondo, battendo i precedenti record di partecipazione. Il concorso per l'energia intelligente si è concluso all'inizio di aprile con 785 candidature provenienti da 76 Paesi e regioni, il numero più alto nei suoi quattro anni di storia. Dietro le impressionanti statistiche si nasconde un v...
Energie-innovatie wereldwijd in opmars: TERA-Award ontvangt recordaantal van 785 inzendingen HONG KONG, April 27, 2025 (GLOBE NEWSWIRE) -- De belangstelling voor klimaattechnologie neemt wereldwijd toe: nog nooit meldden zich zoveel deelnemers aan voor de TERA-Award als dit jaar. De inschrijving voor de wedstrijd rond slimme energieoplossingen sloot begin april met 785 inzendingen uit 76 landen en regio’s, het hoogste aantal sinds de competitie vier jaar geleden van start ging. Achter deze indrukwekkende cijfers gaat een wereld van innovatie schuil, verspreid over zes categorieën. Hernie...
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events...
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the 2025 Ame...
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities Saint Herblain (France), April 26, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in ...
Valneva fait un point sur la recommandation d’utilisation de son vaccin contre le chikungunya par les autorités françaises Saint Herblain (France), le 26 avril 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’autorité publique de santé en France, la Haute Autorité de Santé (HAS), a mis à jour sa recommandation concernant l'utilisation du vaccin à dose unique de Valneva, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya (CHIKV) suite à une notification d'effets indésirables graves chez des personnes â...
New share capital registered Frøya, Norway, 26 April 2025: Reference is made to the stock exchange announcement by Kaldvik AS ("Kaldvik", the "Company") on 22 April 2025, regarding the issuance of new shares in connection with the acquisition of key assets in the fish farming value chain on the east-coast of Iceland. The share capital increase has now been registered with the Norwegian Register of Business Enterprises. The Company’s new registered share capital is NOK 12,851,120.10, divided on 128,511,201 shares, each carrying one vote at the Company’s general meeting and each with a nom...
Summons for the Annual General Meeting of P/F Atlantic Petroleum Summons for the Annual General Meeting of P/F Atlantic Petroleum The Annual General Meeting of P/F Atlantic Petroleum is hereby called. The meeting will be held at the premises of Advokatfelagið, Lucas Debesargøta 8, 100 Tórshavn, Faroe Islands. on Friday 23rd May 2025 at 15:00 (Faroese time) with the following agenda: 1. Election of Chairman of the Meeting. 2. The Board of Directors’ statement of the Company’s activity during the previous accounting year. 3. Presentation of audited Annual Accounts for approval. ...
Kardium redovisar starka ettårsresultat och hög säkerhet i PULSAR-IDE-studien Kardium Inc. – en av Corlines kunder och användare av CHS™-ytan på sin Globe®-kateter för behandling av hjärtarytmi – har presenterat ettårsuppföljningen av den registreringsgrundande PULSAR-IDE-studien vid den vetenskapliga kongressen Heart Rhythm Society 2025. Studien nådde sina effektmål med 100 % lyckad pulmonell venisolering (PVI) i samband med behandlingstillfället och 78 % vid 12-månadersuppföljningen. Säkerhetsprofilen var mycket stark med 0 % kateterrelaterade säkerhetshändelser. CHS™-coatningen på Globe...
A director at Pangea Natural Foods Inc sold 1,920,000 shares at 0.100CAD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Two Directors at The Real Brokerage Inc sold/bought 166,666 shares at 4.661USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
A director at Warom Technology Incorporated Co sold 800,000 shares at 17.450CNY and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.